Harvard spinout TScan Therapeutics has successfully listed on the Nasdaq Global Market.

Osage University Partners has returned to back the cancer and inflammatory drug developer based on research from multiple universities.

WUSTL spinout Wugen has collected $172m in a series B round to progress its pipeline targeting several cancer indications.

The gene editing technology developer is the latest spinout emerging out of the lab of David Liu at Broad Institute.

Patient Square Capital has led a series B round for the Stanford-linked gene therapy developer, which previously collected $80.5m in May last year.

The IGBMC spinout was set up by Satt Conectus and is now seeking a listing in the US with a price range of $15 to $17.

IP Group has returned for a series C round for the PNNL spinout, having already backed the series A and B rounds.

Th heart disease treatment developer has secured $248m in funding since being formed to exploit UT Southwestern and Gladstone Institute research.

The precision oncology platform is based on research by Duke and Hubrecht Institute faculty and the cash will fund technology development and clinical studies.

The fund will invest in companies linked to École Polytechnique, including spinouts, alumni-founded startups or businesses incubated by the school.